Saving fertility for cancer survivors?Young women with cancer often suffer premature ovarian failure premature ovarian failure Cessation of menses before age 40, often accompanied by ↑ serum gonadotropin Etiology Idiopathic, or 2º to ovarian receptor antibodies, viral infection, cytotoxic drugs, RT, etc and thus infertility infertility, inability to conceive or carry a child to delivery. The term is usually limited to situations where the couple has had intercourse regularly for one year without using birth control. after chemotherapy or radiation therapy. There hasn't been a way to protect women against such damage, says Francois Paris of the Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . However, in the October 2000 NATURE MEDICINE, he and his colleagues showed that a compound called sphingosine-1-phosphate, given before anticancer radiation, protects mouse ovaries Ovaries The female sex organs that make eggs and female hormones. Mentioned in: Choriocarcinoma ovaries (ō´v . Now, the researchers report that the drug permits pregnancy after radiation exposure. Before applying radiation, the researchers gave some female mice sphingosine-1-phosphate and others a placebo. After the treatments, 88 percent of mice receiving the drug became pregnant and gave birth, but only 38 percent of placebo-treated females did. The researchers haven't yet seen any chromosomal abnormality in the offspring of the treated group, another indication that the drug protects ovaries from radiation damage. "The signs are very promising," says Paris, noting that preliminary studies in human-cell cultures mirror the findings in mice. He cautions, however, that more safety studies are needed before the compound can be tested in people. |
|
||||||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion